drugset / Trial / NCT00006001

SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

NCT00006001

Phase 2 Terminated 37 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.

Timeline

Start
2000-08
Primary completion
2007-02
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject semaxanib Small molecule Intravenous

Indications